You are here

Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Birmington, Alabama, 35233 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Advanced or recurrent solid malignancy confirmed histologically or cytologically for
which no effective therapy is available.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.

- Measurable disease as outlined by the modified Response Evaluation Criteria in Solid
Tumors (RECIST) criteria.

- Other inclusion applies.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Use of any systemic antitumor agents or any investigational agent within 28 days
before the first dose of test article is administered.

- Prior exposure to SKI-606 or any other Src-kinase inhibitor, major surgery or
radiotherapy within 14 days before the first dose of test article (recovery from
previous surgery should be complete before day 1).

- Active central nervous system (CNS) metastases, as indicated by clinical symptoms,
cerebral edema, requirement for corticosteroids and/or progressive growth (Treated CNS
metastases must be stable for >= 2 weeks before day 1).

- Other exclusion applies.

NCT00195260
Pfizer
Completed
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Neoplasms
NCT02222922
All Genders
18+
Years
Multiple Sites
Breast Neoplasms
NCT01176916
Females
0+
Years
Multiple Sites
Neoplasms by Histologic Type
NCT00878189
All Genders
16+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now